Advanced in Chondrosarcoma

Klaus K. Herfarth

Heidelberg, BW, DE 
Advanced in Chondrosarcoma
Heidelberg, BW, DE 
OverviewLocationsClinical Research

Overview

Klaus Herfarth practices in Heidelberg, Germany. Mr. Herfarth is rated as an Advanced expert by MediFind in the treatment of Chondrosarcoma. His top areas of expertise are Adenoid Cystic Carcinoma, Chordoma, Chondrosarcoma, Laryngectomy, and Thymectomy.

His clinical research consists of co-authoring 197 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 10 articles in the study of Chondrosarcoma.

Gender
Male

Locations

Heidelberg, BW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Hypofractionated Ion Irradiation (Protons or Carbon Ions) of Sacrococcygeal Chordoma
Hypofractionated Ion Irradiation (Protons or Carbon Ions) of Sacrococcygeal Chordoma
Enrollment Status: Active_not_recruiting
Publish Date: December 06, 2023
Intervention Type: Radiation
Study Phase: Phase 2
Evaluation of Inter- and Intrafractional Motion of Liver Tumors Using Interstitial Markers and Implantable Electro-magnetic Radiotransmitters in the Context of Image-guided Radiotherapy (IGRT) - the ESMERALDA Trial
Evaluation of Inter- and Intrafractional Motion of Liver Tumors Using Interstitial Markers and Implantable Electro-magnetic Radiotransmitters in the Context of Image-guided Radiotherapy (IGRT) - the ESMERALDA Trial
Enrollment Status: Withdrawn
Publish Date: May 17, 2018
Intervention Type: Behavioral
Study Phase: Not Applicable
View 1 Less Clinical Trial

197 Total Publications

Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD).
Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD).
Journal: Oral oncology
Published: July 01, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Herfarth's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 40 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile